Abstract:Several aspects of EGFR TKI treatment have been discussed.The issue of TKIs resistance has been treated in some papers. In their Opinion, Bronte G et al discussed the topic of Osimertinib resistance and the possible combination strategies or the use of fourth generation EGFR-TKIs to overcome it. They supposed that in the next future oncologists will be able to address each patients who experience resistance to upfront osimertinib toward a different treatment strategy on the basis of molecular alterations highlighted by liquid biopsy or tumor biopsy. In this line, Carlo Bao et al presented two clinical cases harboring concomitant EGFR and BRAF alterations and treated with Osimertinib. Both cases were responsive to treatment and liquid biopsy results were in accordance with the clinical behaviour. Patients with advanced NSCLC with secondary T790M can benefit from Osimertinib, but the role of this drug in patients who exhibith resistance without T790M or with T790M unknown status is not well established. From the systematic review and meta-analysis performed by Yi XF and colleagues emerged that patients who undergo progression with brain metastasis on first or second generation TKIs can benefit from subsequent Osimertinib regardless T790M status. This represent an important finding that could orientate clinical decision management after Osimertinib resistance.Other types of resistance mechanisms are known, and the role of tumor-associated macrophages (TAMs) is also emerging (1). Previous studies have demonstrated that high infiltration of TAMs is significantly associated with an unfavorable prognosis in NSCLC patients treated with EGFR-TKIs (2). So, the inhibition of TAMs may a potential approach to improving resistance to EGFR-TKIs. In the review reported by Cheng D et al, a number of preclinical studies have been discussed, analysing the combination of EGFR-TKIs with several compound directed versus TAMs. In particular, inhibiting mTOR, AKT and STAT3 pathways, such as the lipid metabolic pathway, could all be possible potenatial strategies to overcome EGFR-TKI resistance.The addition of antiangiogenic treatments to EGFR-TKis was also studied. The systematic review and meta-analysis by Zheng H et al highlighted that the addition of bevacizumab to EGFR-TKI provide significant better PFS and OS, and the benefit is more evident for patients who have ever smoked, aged <75 years and of Asian population. Hsu PC and colleagues reported the results of a study in which first-line bevacizumab was combined with erlotinib or afatinib in EGFR-mutated NSCLC, demonstrating the development of T790M as resistance mechanism in 57.9% of cases. The addition of anti-angiogenic treatment in patients with an acquired resistance to Osimertinib was also demonstrated in a clinical case described by He W et al. In particular, a NSCLC patients harboring acquired EGFR 19Del/T790M/cis-C797S mutation resistance was treated with sintilimab, an anti-VEGF drug and chemotherapy. The patient remained progression-free for 15 months and the regimen was well tolerated. The addition of immunotherapy in EGFR-mutated patients is a controversial topic (3). Microsatellite instability is a rare event in NSCLC, but Yang M et al reported a case of apatients with a rare pulmonary enteric adenocarcinoma with EGFR mutation and MSI-H, who receive benefit from a combination approach of EGFR-TKI plus immune check point inhibitor.Rare EGFR mutations are another important issue object of several studies in the last years. It was reported that afatinib, an irreversible ErbB family inhibitor, is more efficacious in treating patients with uncommon EGFR mutations (4). Dong W et al performed a literature search on studies evaluating the efficacy of afatinib in any line of treatment in NSCLC patients with uncommon EGFR mutations. Their conclusion was that afatinib seems to be effective in patients with the more frequent uncommon EGFR mutations, whereas inconsistent data are present with regard to the other uncommon EGFR alterations, due to the high heterogeneity of them. Christopoulos P et al described seven clinical cases of patients carrying different uncommon EGFR mutations treated with afatinib. Overall, patients responded to afatinib, with six partial response and three durable responses. Interestingly, co-mutations did not preclude sensitivity to the drug, with durable response observed also in patients exhibiting cooccurring TP53 or CDKN2A mutations. Another case report was reported by Wang P et al, describing a patient carrying two exon 18 mutations and who acquired an EGFR amplification after treatment with osimertinib. The patient showed a partial response to neratinib. Also, a further case report of a patient carrying an EGFR kinase domain duplication was reported by Lin H and colleagues. The patient received the 3rd generation EGFR-TKI furmonertinib and obtained a partial response in primary tumor and in -Abstract Truncated-

EGFR-mutant non-small cell lung cancer patients harboring CDK4 amplification show favorable response to afatinib: Two case reports

Case Report: Dacomitinib Overcomes Osimertinib Resistance in NSCLC Patient Harboring L718Q Mutation: A Case Report

Non-small-cell Lung Cancer with Epidermal Growth Factor Receptor L861Q-L833F Compound Mutation Benefits from Both Afatinib and Osimertinib: A Case Report.

Activity of afatinib in patients with NSCLC harboring novel uncommon EGFR mutations with or without co-mutations: a case report

Durable response to afatinib in an advanced lung adenocarcinoma patient with an EGFR L858R/G729A compound mutation: a case report

Durable clinical benefit from afatinib in a lung adenocarcinoma patient with acquired EGFR L718V mutation-mediated resistance towards osimertinib: a case report and literature review

Osimertinib and palbociclib in an EGFR-mutated NSCLC with primary CDK4 amplification after progression under osimertinib

Afatinib overcoming resistance to icotinib and osimertinib in NSCLC with leptomeningeal metastasis in patients with acquired EGFR L858R/T790M or L858R/S768I mutations: Two case reports

Editorial: Advances in the use of EGFR TKIs in the treatment of NSCLC

Acquired multiple EGFR mutations‐mediated resistance to a third‐generation tyrosine kinase inhibitor in a patient with lung adenocarcinoma who responded to afatinib: A case report and literature review

Case Report: A patient with the rare third-generation TKI-resistant mutation EGFR L718Q who responded to afatinib plus cetuximab combination therapy

Concurrent Genetic Alterations and Other Biomarkers Predict Treatment Efficacy of EGFR-TKIs in EGFR-Mutant Non-Small Cell Lung Cancer: A Review

Successful Treatment of a Patient with NSCLC Carrying Uncommon Compound L861Q/G719X Epidermal Growth Factor Receptor Mutations Using Afatinib

Three Novel EGFR Mutations (750_758del, I759S, T751_I759delinsS) in One Patient with Metastatic Non-Small Cell Lung Cancer Responding to Osimertinib: A Case Report

Resolving Resistance to Osimertinib Therapy With Afatinib in an NSCLC Patient With <i>EGFR</i> L718Q Mutation

Case report: EGFR fusion mutation combined with EGFR amplification responds to EGFR-TKI therapy

Efficacy and potential resistance mechanisms of afatinib in advanced non-small cell lung cancer patients with EGFR G719X/L861Q/S768I

Combination therapy with afatinib and bevacizumab in an <i>EGFR</i>-mutated non-small cell lung cancer patient with acquired ERBB2 amplification A case report

Therapeutic strategies to overcome ALK-fusion and BRAF-mutation as acquired resistance mechanism in EGFR-mutated non-small cell lung cancer: two case reports

Dacomitinib overcomes acquired resistance to osimertinib in advanced NSCLC patients with EGFR L718Q mutation: A two-case report

A case report of a dramatic response to Afatinib in a patient with advanced adenosquamous carcinoma lung cancer (ASC) harboring EGFR L861R